ESR1 and cancer: Since aberrant activity of the receptor or its partners is considered the main cause of endocrine resistance [55], this result is of particular interest as it shows a new potential approach to effectively interfere with ERα signaling in cancer cells by targeting the complex formed by the three factors investigated here.